ArticleJournal of clinical microbiology2016
Development of Rapid Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Burkholderia pseudomallei.
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 70 citations in OpenAlex.
- Development and international multicenter evaluation of a second-generation immunochromatography test for the serological diagnosis of melioidosis.PLoS neglected tropical diseases · 2026Article
- Development of an antigen detection test kit (Melioidosis-ATK) for point-of-care diagnosis of melioidosis.Microbiology spectrum · 2026Article
- Stability assessment of whole cell ELISA for Burkholderia pseudomallei antibodies detection.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Evidence of populational Burkholderia pseudomallei exposure in Madagascar.PLoS neglected tropical diseases · 2025Article
- Postexposure Antimicrobial Drug Therapy in Goats Infected with Burkholderia pseudomallei.Emerging infectious diseases · 2025Article
- Performance of Antibody-Detection Tests for Human Melioidosis: A Systematic Review and Meta-analysis.The Malaysian journal of medical sciences : MJMS · 2024Review
- Diagnostic accuracy of DPP Fever Panel II Asia tests for tropical fever diagnosis.PLoS neglected tropical diseases · 2024Article
- Burkholderia pseudomallei and melioidosis.Nature reviews. Microbiology · 2024Review
- Effectiveness of UmoniumBMC infectious diseases · 2024Article
- Development of a Novel Internally Controlled HrpB1 Gene-Based Real-Time qPCR Assay for Detection of Burkholderia pseudomallei.Molecular diagnosis & therapy · 2024Article
- Prospective Analysis of Antibody Diagnostic Tests and TTS1 Real-Time PCR for Diagnosis of Melioidosis in Areas Where It Is Endemic.Journal of clinical microbiology · 2023Article
- NHP BurkPx: A multiplex serodiagnostic bead assay to monitor Burkholderia pseudomallei exposures in non-human primates.PLoS neglected tropical diseases · 2023Article
- Development and evaluation of a multiplex serodiagnostic bead assay (BurkPx) for accurate melioidosis diagnosis.PLoS neglected tropical diseases · 2023Article
- Deciphering the human antibody response againstFrontiers in immunology · 2023Article
- Serodiagnosis of Abdominal Abscess Caused byInfection and drug resistance · 2023Article
- Functional Activities of O-Polysaccharide and Hemolysin Coregulated Protein 1 Specific Antibodies Isolated from Melioidosis Patients.Infection and immunity · 2022Article
- Evaluation of antigen-detecting and antibody-detecting diagnostic test combinations for diagnosing melioidosis.PLoS neglected tropical diseases · 2021Article
- Evaluation of a genus-specific rGroELScientific reports · 2021Article
- Use of RecombinantPathogens (Basel, Switzerland) · 2021Article
- BipD ofMicroorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Burkholderia pseudomallei, the causative agent of melioidosis, is an environmental bacillus found in northeast Thailand. The mortality rate of melioidosis is ∼40%. An indirect hemagglutination assay (IHA) is used as a reference serodiagnostic test; however, it has low specificity in areas where the background seropositivity of healthy people is high. To improve assay specificity and reduce the time for diagnosis, four rapid enzyme-linked immunosorbent assays (ELISAs) were developed using two purified polysaccharide antigens (O-polysaccharide [OPS] and 6-deoxyheptan capsular polysaccharide [CPS]) and two crude antigens (whole-cell [WC] antigen and culture filtrate [CF] antigen) of B. pseudomallei The ELISAs were evaluated using serum samples from 141 culture-confirmed melioidosis patients from Thailand along with 188 healthy donors from Thailand and 90 healthy donors from the United States as controls. The areas under receiver operator characteristic curves (AUROCC) using Thai controls were high for the OPS-ELISA (0.91), CF-ELISA (0.91), and WC-ELISA (0.90), while those of CPS-ELISA (0.84) and IHA (0.72) were lower. AUROCC values using U.S. controls were comparable to those of the Thai controls for all ELISAs except IHA (0.93). Using a cutoff optical density (OD) of 0.87, the OPS-ELISA had a sensitivity of 71.6% and a specificity of 95.7% for Thai controls; for U.S. controls, specificity was 96.7%. An additional 120 serum samples from tuberculosis, scrub typhus, or leptospirosis patients were evaluated in all ELISAs and resulted in comparable or higher specificities than using Thai healthy donors. Our findings suggest that antigen-specific ELISAs, particularly the OPS-ELISA, may be useful for serodiagnosis of melioidosis in areas where it is endemic and nonendemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.